Ascentage Pharma announced that it has entered into a clinical collaboration with AstraZeneca Investment Co., Ltd. . The two companies will jointly conduct a registrational Phase III study of the.
Global Registrational Phase III Study of Bcl-2 Inhibitor Lisaftoclax in Treatment-Naïve Patients with CLL/SLL Approved by the China CDE streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.
Ascentage Pharma announced that the Center for Drug Evaluation of China National Medical Products Administration has approved a global pivotal registrational Phase III study designed to evaluate a.